China National Accord Medicines Corporation Ltd Class A

As of June 30, 2026, China National Accord Medicines Corporation Ltd Class B carries a market capitalization of 13.97B, placing it among publicly traded companies globally. Its enterprise value stands at 14.48B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

China National Accord Medicines Corporation Ltd Class B's next confirmed earnings release is scheduled for April 14, 2027.

As of June 30, 2026, China National Accord Medicines Corporation Ltd Class B has 1.20B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, China National Accord Medicines Corporation Ltd Class B maintains a current ratio of 1.58, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, China National Accord Medicines Corporation Ltd Class B recorded 302.82M in income tax expense.

As of the close on October 23, 2026, China National Accord Medicines Corporation Ltd Class B's stock has declined approximately 1.30% over the past 52 weeks. The 50-day moving average sits at 12.01, while the 200-day moving average is 12.27.

As of June 30, 2026, China National Accord Medicines Corporation Ltd Class B holds 6.86B in cash and equivalents against 3.87B in total debt, resulting in a net debt position of -4.74B. Total book value stands at 21.81B, with working capital of 16.74B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, China National Accord Medicines Corporation Ltd Class B paid dividends of 0.72 per share.

China National Accord Medicines Corporation Ltd Class B's most recent stock split took place on June 24, 2026 with a 10:11 split ratio.